دورية أكاديمية

Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses.

التفاصيل البيبلوغرافية
العنوان: Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses.
المؤلفون: Kruglov, Andrey A., Bondareva, Marina A., Gogoleva, Violetta S., Semin, Iaroslav K., Astrakhantseva, Irina V., Zvartsev, Ruslan, Lunin, Aleksandr S., Apolokhov, Vasiliy D., Shustova, Elena Yu, Volok, Viktor P., Ustyugov, Aleksey A., Ishmukhametov, Aydar A., Nedospasov, Sergei A., Kozlovskaya, Liubov I., Drutskaya, Marina S.
المصدر: European Journal of Immunology; Mar2024, Vol. 54 Issue 3, p1-17, 17p
مصطلحات موضوعية: SARS-CoV-2 Omicron variant, T cells, ANTIBODY formation, SARS-CoV-2, VIRUS diseases
مصطلحات جغرافية: WUHAN (China)
مستخلص: COVID‐19 is a systemic inflammatory disease initiated by SARS‐CoV‐2 virus infection. Multiple vaccines against the Wuhan variant of SARS‐CoV‐2 have been developed including a whole virion beta‐propiolactone‐inactivated vaccine based on the B.1.1 strain (CoviVac). Since most of the population has been vaccinated by targeting the original or early variants of SARS‐CoV‐2, the emergence of novel mutant variants raises concern over possible evasion of vaccine‐induced immune responses. Here, we report on the mechanism of protection by CoviVac, a whole virion‐based vaccine, against the Omicron variant. CoviVac‐immunized K18‐hACE2 Tg mice were protected against both prototype B.1.1 and BA.1‐like (Omicron) variants. Subsequently, vaccinated K18‐hACE2 Tg mice rapidly cleared the infection via cross‐reactive T‐cell responses and cross‐reactive, non‐neutralizing antibodies recognizing the Omicron variant Spike protein. Thus, our data indicate that efficient protection from SARS‐CoV‐2 variants can be achieved by the orchestrated action of cross‐reactive T cells and non‐neutralizing antibodies. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00142980
DOI:10.1002/eji.202350664